注射用重组人尿激酶原在急性心肌梗死患者院前溶栓中的应用  

Application of Recombinant Human Prourokinase for Injection in Pre-hospital Thrombolysis in Patients with Acute Myocardial Infarction

作　　者：吕化 Lv Hua(Department of Critical Care Medicine,Yancheng District People's Hospital,Luohe 462000)

机构地区：[1]漯河市郾城区人民医院重症医学科,漯河462000

出　　处：《数理医药学杂志》2022年第3期406-408,共3页Journal of Mathematical Medicine

摘　　要：目的:研究注射用重组人尿激酶原在急性心肌梗死患者院前溶栓中的应用。方法:选取2018年10月~2019年10月医院收治的急性心肌梗死患者112例,通过随机数字表法,分为对照组和观察组各56例,对照组采用常规溶栓疗法,观察组采用注射用重组人尿激酶原,比较两组的治疗效果及不良反应情况,同时比较两组不良心脏事件和出血的具体发生率。结果:观察组治疗总有效率为92.86%,高于对照组的71.43%,有显著差异(P<0.05)。观察组不良反应发生率为3.57%,低于对照组的28.57%,有显著差异(P<0.05)。观察组心脏不良事件发生率为0.00%,低于对照组的10.71%,有显著差异(P<0.05)。观察组出血发生率为3.57%,低于对照组的17.86%,有显著差异(P<0.05)。结论:在急性心肌梗死患者院前溶栓治疗中,使用注射用重组人尿激酶原进行治疗,能有效提高治疗效果,减少不良反应,减少不良心脏事件和出血,具有较高的临床价值。Objective:To study the application of recombinant human prourokinase for injection in pre-hospital thrombolysis in patients with acute myocardial infarction.Methods:112 patients with acute myocardial infarction admitted to a hospital from October 2018 to October 2019 were selected and randomly divided into control group and observation group,with 56 patients in each group.The control group was treated with routine thrombolytic therapy,and the observation group was treated with recombinant human prourokinase for injection.The therapeutic effect and adverse reactions of the two groups were compared,at the same time,the incidence of cardiac adverse events and bleeding in the two groups were compared.Results:The total effective rate was 92.86%in the observation group,which was higher than 71.43%in the control group,with significant difference(P<0.05).The incidence of adverse reactions in the observation group was 3.57%,which was lower than that in the control group(28.57%),with significant difference(P<0.05).The incidence of cardiac adverse events in the observation group was 0.00%,which was lower than 10.71%in the control group,with significant difference(P<0.05).The incidence of bleeding in the observation group was 3.57%,which was lower than 17.86%in the control group,with significant difference(P<0.05).Conclusion:In pre-hospital thrombolytic therapy for patients with acute myocardial infarction,the use of recombinant human urokinase for injection can effectively improve the therapeutic effect,reduce adverse reactions,and reduce the occurrence of adverse cardiac events and bleeding.It has high clinical value.

关 键 词：注射用 重组人尿激酶原 急性心肌梗死 院前溶栓治疗 

分 类 号：R542.2[医药卫生—心血管疾病]